Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Homologous Recombination

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

Blood cancer journal·2026

Same author

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Blood·2026

Same author

Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.

Cancers·2026

Same author

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Cells·2026

Same author

Mechanistically Defined Epoxide- and Aziridine-2-carboxamide Electrophiles Enable Stereoselective Covalent Ribonucleic Acid Modulation.

Journal of the American Chemical Society·2026

Same author

Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.

Journal for immunotherapy of cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

CRISPR application in hematological disorders: from bench to bedside.

Francesco Ladisa¹, Eugenio Morelli², Debora Soncini³

¹IRCCS Ospedale Policlinico San Martino, Italy.

|June 9, 2026

Summary

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing is now a validated therapy for blood disorders like sickle cell disease. This technology is also advancing treatments for blood cancers and improving cellular therapies.

More Related Videos

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Related Experiment Videos

Last Updated: Jun 11, 2026

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Area of Science:

Hematology
Genetics
Immunology

Background:

CRISPR-Cas genome editing has transitioned from research to clinical application in hematology.
Successful treatments for inherited blood disorders demonstrate the safety and efficacy of genetic modification in hematopoietic cells.

Purpose of the Study:

To review recent CRISPR-based advancements in benign and malignant hematologic diseases.
To compare different CRISPR editing modalities and discuss clinical trial data.
To identify translational challenges and future priorities for CRISPR therapeutics in hematology.

Main Methods:

Review of recent CRISPR-based advances across benign and malignant hematologic diseases.
Comparison of major editing modalities: nuclease-mediated disruption, base editing, prime editing, and CRISPR-based transcriptional modulation.
Synthesis of preclinical studies and emerging clinical trial data.

Main Results:

CRISPR editing is effective for inherited blood diseases and shows promise in understanding and treating hematologic malignancies.
Engineered cellular therapies using CRISPR are being developed for enhanced antitumor activity.
Various CRISPR editing modalities offer different approaches for genetic modification.

Conclusions:

CRISPR technology is a powerful tool in hematology, with significant progress in treating genetic blood disorders and cancer.
Addressing challenges in delivery, scalability, safety, and long-term effects is crucial for broader clinical adoption.
Continued innovation in CRISPR technologies will drive precise, durable, and mechanism-informed therapeutic strategies in hematology.